[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-failure-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-failure-patients":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100627382","ted-rogers-understanding-of-exacerbations-in-heart-failure-2-monitor-100627382",false,"NCT07447908","Ted Rogers Understanding of Exacerbations in Heart Failure 2: Monitor","Ted Rogers Understanding of Exacerbations in Heart Failure 2 (TRUE-HF2): Observational Study","TRUE-HF 2","Inclusion Criteria:\n\n* broad age range (\\> 18 years of age)\n* NT-proBNP \\> 400 or 1000 if in AF\n* Within 3 months post discharge from HF hospitalization\u002F HF ED visit\u002F HF rapid clinic visit with intensification of diuretic therapy\n* NYHA functional class I-IV, heart failure with reduced and preserved ejection fraction\n* Literacy in English\n* Patient provided informed consent\n\nExclusion Criteria:\n\n* Unable to perform a CPET based on the standard protocol\n* End stage renal disease requiring dialysis\n* Living with LVAD\n* MRP deems patient unfit for the study\n* Post heart transplant","ALL","18 Years",{"count":20,"type":21},360,"ESTIMATED","1 Year","OBSERVATIONAL","Heart Failure (HF) is a complex disease associated with the highest burden of cost to the healthcare system. The cardiopulmonary exercise test (CPET) is instrumental in determining the prognosis of patients with HF. This multicentre study will validate whether aggregate biometric data from the Apple Watch combined with demographic, cardiac, and biomarker testing can improve our ability to predict heart failure outcomes among a diverse outpatient HF population.",[26,27,28,29,30],"Heart Failure","Heart Failure - NYHA II - IV","Heart Failure Patients","Cardiopulmonary Exercise Test","Apple Watch",[30,32,26,33,34,35,36],"CPET","Artificial Intelligence","Wearable Technology","Wearable","Remote monitoring","NOT_YET_RECRUITING","2026-02-25",{"date":40,"type":41},"2026-03-04","ACTUAL",{"date":43,"type":21},"2026-03-16",{"date":45,"type":21},"2029-09",{"name":47,"class":48},"University Health Network, Toronto","OTHER",3,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100548851","soluble-st2-in-patients-with-heart-failure-100548851","NCT06426368","Soluble ST2 in Patients With Heart Failure\"","\" Prognostic Value of Soluble ST2 Beyond B-Type Natriuretic Peptide in Management of Patients With Heart Failure\"","Inclusion Criteria:\n\n* patients 18-80 years.\n* Both sexes will be included.\n* including signs and symptoms of HF (e.g., elevated jugular venous pressure and altered apical beat position), altered LVEF (\\\u003C 40%; 40%-49%; ≥ 50%)\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years\n* Patients with documented evidence of cardiogenic shock .\n* Patients with Acute coronary syndrome within 30 days.\n* chronic kidney disease patients with glomerular filtration rate \\\u003C 30\n* Patients with interstitial pulmonary fibrosis .","80 Years",{"count":59,"type":21},100,"1. The aim of this study was to explore the relationship between peripheral circulating serum soluble suppression of tumorigenicity-2 (sST2) levels and inflammatory biomarkers in patients with heart failure\n2. Additive role of sST2 to NPs in of heart failure patients",[28],"2024-05-17",{"date":64,"type":41},"2024-05-23",{"date":66,"type":21},"2024-07-01",{"date":68,"type":21},"2027-01-01",{"name":70,"class":48},"Assiut University"]